FDA Post-Election Landscape Debated By Former Agency Officials
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers should expect FDA to defer decisions with policy consequences until after the November Presidential election, according to Alston & Bird Partner Marc Scheineson
You may also be interested in...
Mentor Files Silicone Implant PMA Amendment, Catches Up To Inamed
Mentor's submission of a silicone gel-filled breast implant PMA amendment, announced Aug. 31, places the aesthetic firm nearly on par with sole U.S. competitor Inamed
Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?
Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry Administration takes over the White House in November
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”